Literature DB >> 29212733

Successful Ovarian Stimulation for Fertility Preservation in a Patient with Chronic Myeloid Leukemia: Switch from Nilotinib to Interferon-α.

Smaranda Gazdaru1, Lucien Perey2, Anne Rosselet3, Patrice Mathevet4, Yves Chalandon5,6, Nicolas Vulliemoz7.   

Abstract

The development of tyrosine-kinase inhibitors (TKIs) has improved survival of patients with chronic myeloid leukemia (CML). Some patients may become resistant to TKIs and require hematopoietic stem cell transplant (HSCT) that is highly gonadotoxic. Fertility preservation with ovarian stimulation might be indicated but is challenging if patients need to remain on TKIs until HSCT because TKIs may compromise follicular development and response to ovarian stimulation. We report the case of a patient with CML resistant to TKI and planned for an HSCT, in which treatment by TKI was replaced by interferon-α before and during ovarian stimulation for fertility preservation. Successful ovarian stimulation was performed, allowing cryopreservation of nine zygotes. Hematopoietic stem cell transplantation was performed, and at present, 3 years later, the patient presents a sustained major molecular response. © AlphaMed Press 2017.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29212733      PMCID： PMC6067946          DOI： 10.1634/theoncologist.2017-0381

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


  10 in total

1.  Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

Authors:  J M Goldman; J V Melo
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

2.  Can only partial T-cell depletion of the graft before hematopoietic stem cell transplantation mitigate graft-versus-host disease while preserving a graft-versus-leukemia reaction? A prospective phase II study.

Authors:  Yves Chalandon; Eddy Roosnek; Bernadette Mermillod; Laurent Waelchli; Claudine Helg; Bernard Chapuis
Journal:  Biol Blood Marrow Transplant       Date:  2006-01       Impact factor: 5.742

Review 3.  Managing pregnancy in chronic myeloid leukaemia.

Authors:  Renuka Palani; Dragana Milojkovic; Jane F Apperley
Journal:  Ann Hematol       Date:  2015-03-27       Impact factor: 3.673

4.  Will imatinib compromise reproductive capacity?

Authors:  Alberuni M Zamah; Michael J Mauro; Brian J Druker; Kutluk Oktay; Merrill J Egorin; Marcelle I Cedars; Mitchell P Rosen
Journal:  Oncologist       Date:  2011-09-23

Review 5.  Growth factors controlling ovarian functions.

Authors:  Alexander V Sirotkin
Journal:  J Cell Physiol       Date:  2011-09       Impact factor: 6.384

6.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

Authors:  Brian J Druker; François Guilhot; Stephen G O'Brien; Insa Gathmann; Hagop Kantarjian; Norbert Gattermann; Michael W N Deininger; Richard T Silver; John M Goldman; Richard M Stone; Francisco Cervantes; Andreas Hochhaus; Bayard L Powell; Janice L Gabrilove; Philippe Rousselot; Josy Reiffers; Jan J Cornelissen; Timothy Hughes; Hermine Agis; Thomas Fischer; Gregor Verhoef; John Shepherd; Giuseppe Saglio; Alois Gratwohl; Johan L Nielsen; Jerald P Radich; Bengt Simonsson; Kerry Taylor; Michele Baccarani; Charlene So; Laurie Letvak; Richard A Larson
Journal:  N Engl J Med       Date:  2006-12-07       Impact factor: 91.245

7.  Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group.

Authors:  A Hochhaus; A Reiter; S Saussele; A Reichert; M Emig; J Kaeda; B Schultheis; U Berger; P C Shepherd; N C Allan; R Hehlmann; J M Goldman; N C Cross
Journal:  Blood       Date:  2000-01-01       Impact factor: 22.113

Review 8.  Kit ligand and c-Kit have diverse roles during mammalian oogenesis and folliculogenesis.

Authors:  K J Hutt; E A McLaughlin; M K Holland
Journal:  Mol Hum Reprod       Date:  2006-02-15       Impact factor: 4.025

9.  The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene.

Authors:  Y Ben-Neriah; G Q Daley; A M Mes-Masson; O N Witte; D Baltimore
Journal:  Science       Date:  1986-07-11       Impact factor: 47.728

10.  The Tyrosine Kinase Inhibitor Sunitinib Affects Ovulation but Not Ovarian Reserve in Mouse: A Preclinical Study.

Authors:  Valérie Bernard; Justine Bouilly; Piet Kramer; Nadège Carré; Martin Schlumberger; Jenny A Visser; Jacques Young; Nadine Binart
Journal:  PLoS One       Date:  2016-04-01       Impact factor: 3.240
  10 in total
  5 in total

Review 1.  Combination Therapies in Chronic Myeloid Leukemia for Potential Treatment-Free Remission: Focus on Leukemia Stem Cells and Immune Modulation.

Authors:  Hui Mu; Xiaojian Zhu; Hui Jia; Lu Zhou; Hong Liu
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

Review 2.  Fertility considerations in targeted biologic therapy with tyrosine kinase inhibitors: a review.

Authors:  Anupama Rambhatla; Michael R Strug; Jessica Garcia De Paredes; Marcos I Cordoba Munoz; Mili Thakur
Journal:  J Assist Reprod Genet       Date:  2021-04-07       Impact factor: 3.357

3.  Fertility Preservation in Leukemia.

Authors:  Zeev Blumenfeld
Journal:  Oncologist       Date:  2018-02-07

4.  Successful ovarian stimulation and pregnancy in an infertile woman with chronic myeloid leukemia.

Authors:  Silvina J Rios; Lorena Martínez-Montesinos; Cristina Aroca; Raul Teruel-Montoya; Francisca Ferrer-Marín
Journal:  J Assist Reprod Genet       Date:  2020-08-06       Impact factor: 3.412

5.  Management of Chronic Myeloid Leukemia and Pregnancy: A Bibliometric Analysis (2000-2020).

Authors:  Yue Wang; Liqing Jiang; Baoxuan Li; Yan Zhao
Journal:  Front Oncol       Date:  2022-03-07       Impact factor: 6.244
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.